Walvax Biotechnology (SHE:300142) subsidiary Yuxi Walvax received marketing authorization from Egypt's drug regulator for its 13-valent pneumococcal conjugate vaccine,
The vaccine, which protects against 13 serotypes responsible for serious infections, is intended for children aged six weeks to under five years, according to a Thursday filing with the Shenzhen bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments